银杏生物工程

最新新闻

• 评级变动
  TD Cowen Maintains Ginkgo Bioworks(DNA.US) With Buy Rating, Maintains Target Price $12
  \u5e02\u573a\u8d44\u8baf · 2026/5/8
• 公司公告
  Sonim Technologies | 3: Initial statement of beneficial ownership of securities-10% Owner DNA Holdings Venture Inc.
  SEC · 2026/2/21
• 评级变动
  TD Cowen Maintains Ginkgo Bioworks(DNA.US) With Buy Rating, Cuts Target Price to $12
  \u5e02\u573a\u8d44\u8baf · 2026/1/8
• 公司公告
  DNA Chip Research: Change report (special case target stocks, etc.)
  EDINET · 2025/6/6
• TD Cowen Downgrades Ginkgo Bioworks(DNA.US) to Hold Rating, Cuts Target Price to $9
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 公司公告
  DNA Chip Research: Interim report.
  EDINET · 2025/6/3
• 公司公告
  DNA X | 8-K: DNA X, Inc. Reports First Quarter 2026 Financial Results
  SEC · 2026/5/21
• 评级变动
  BTIG Maintains Ginkgo Bioworks(DNA.US) With Sell Rating, Cuts Target Price to $5
  \u5e02\u573a\u8d44\u8baf · 2026/3/12
• 评级变动
  William Blair Maintains Ginkgo Bioworks(DNA.US) With Sell Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• BTIG Maintains Ginkgo Bioworks(DNA.US) With Sell Rating, Maintains Target Price $5
  \u5e02\u573a\u8d44\u8baf · 2026/9/4
• Press Release: DNA X, Inc. Reports Second Quarter 2026 Financial Results
  Dow Jones · 2026/8/20
• 评级变动
  TD Cowen Maintains Ginkgo Bioworks(DNA.US) With Buy Rating, Cuts Target Price to $14
  \u5e02\u573a\u8d44\u8baf · 2025/11/7
• 评级变动
  BTIG Maintains Ginkgo Bioworks(DNA.US) With Sell Rating, Raises Target Price to $9
  \u5e02\u573a\u8d44\u8baf · 2025/8/25
• 评级变动
  William Blair Initiates Ginkgo Bioworks(DNA.US) With Sell Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• 评级变动
  TD Cowen Maintains Ginkgo Bioworks(DNA.US) With Buy Rating, Raises Target Price to $18
  \u5e02\u573a\u8d44\u8baf · 2025/10/14
• 公司公告
  8-K: Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. Hayward
  SEC · 2025/6/18
• Kala Bio and Virotek Sign Letter of Intent With U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products
  GlobeNewswire · 2026/9/24
• Ginkgo Bioworks (DNA.US) will release its earnings report after market close on August 5.
  \u5e02\u573a\u8d44\u8baf · 2026/7/31
• 评级变动
  TR | OpenAI - 4o Maintains Ginkgo Bioworks(DNA.US) With Hold Rating, Raises Target Price to $12
  \u5e02\u573a\u8d44\u8baf · 2025/8/12
• 评级变动
  Analysts Conflicted on These Healthcare Names: Ginkgo Bioworks Holdings (DNA), Xencor (XNCR) and Alto Neuroscience, Inc. (ANRO)
  TipRanks · 2026/5/11

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。